Stay updated on Sacituzumab Govitecan in Metastatic Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab Govitecan in Metastatic Solid Tumors Clinical Trial page.

Latest updates to the Sacituzumab Govitecan in Metastatic Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedThe page’s revision/version label has been updated from v3.5.2 to v3.5.3, indicating a site release rather than a substantive change to the study information.SummaryDifference0.0%

- Check10 days agoChange Detected- Revision: v3.5.2 is now shown, replacing the previous Revision: v3.5.0.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check39 days agoChange DetectedRevision: v3.5.0 released, replacing the previous v3.4.3.SummaryDifference0.0%

- Check46 days agoChange Detected- Revision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check75 days agoChange DetectedAdded site revision note v3.4.2 and removed prior notices about government funding lapse and NIH operating status (v3.4.1).SummaryDifference0.3%

- Check82 days agoChange DetectedAdded a Results Posted date (2026-01-30) and associated results data for the TROPiCS-03 study across multiple cohorts. Updated the trial design to non-randomized, parallel assignment and expanded cohort descriptions (NSCLC subtypes, HNSCC, EC, ES-SCLC) with revised inclusion criteria and treatment regimens.SummaryDifference5%

Stay in the know with updates to Sacituzumab Govitecan in Metastatic Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in Metastatic Solid Tumors Clinical Trial page.